According to WHO's latest report, Belarus is listed as a multidrug-resistant TB high burden country. We are supporting the Ministry of Health in four TB facilities across Minsk city and region. Minsk is also a site for two clinical studies into shorter, innovative TB regimens which use newer TB drugs, TB PRACTECAL and endTB.
In Orsha, teams also treat inmates of a prison with DR-TB and co-infections such as hepatitis C, for which they receive direct-acting antiviral drugs.
Our activities in 2023 in Belarus
Data and information from the International Activity Report 2023.
37
37
€1.7 M
1.7M
2015
2015
220
22
Voices from the field
This experience has changed our outlook on life.Polina, a patient taking part in MSF's TB trial